- Home
- BQ vs ENSC Comparison
BQ vs ENSC Comparison
Compare BQ & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BQ
- ENSC
- Stock Information
- Founded
- BQ 2008
- ENSC 2003
- Country
- BQ China
- ENSC United States
- Employees
- BQ N/A
- ENSC N/A
- Industry
- BQ Other Specialty Stores
- ENSC Biotechnology: Pharmaceutical Preparations
- Sector
- BQ Consumer Discretionary
- ENSC Health Care
- Exchange
- BQ Nasdaq
- ENSC Nasdaq
- Market Cap
- BQ 6.0M
- ENSC 4.9M
- IPO Year
- BQ 2020
- ENSC N/A
- Fundamental
- Price
- BQ $2.29
- ENSC $2.28
- Analyst Decision
- BQ
- ENSC
- Analyst Count
- BQ 0
- ENSC 0
- Target Price
- BQ N/A
- ENSC N/A
- AVG Volume (30 Days)
- BQ 34.4K
- ENSC 64.8K
- Earning Date
- BQ 07-15-2025
- ENSC 08-13-2025
- Dividend Yield
- BQ N/A
- ENSC N/A
- EPS Growth
- BQ N/A
- ENSC N/A
- EPS
- BQ N/A
- ENSC N/A
- Revenue
- BQ $81,208,354.00
- ENSC $6,224,081.00
- Revenue This Year
- BQ N/A
- ENSC N/A
- Revenue Next Year
- BQ N/A
- ENSC $1,381.48
- P/E Ratio
- BQ N/A
- ENSC N/A
- Revenue Growth
- BQ N/A
- ENSC 256.35
- 52 Week Low
- BQ $1.62
- ENSC $1.62
- 52 Week High
- BQ $7.40
- ENSC $14.67
- Technical
- Relative Strength Index (RSI)
- BQ 58.56
- ENSC 53.77
- Support Level
- BQ $1.92
- ENSC $2.15
- Resistance Level
- BQ $2.14
- ENSC $2.34
- Average True Range (ATR)
- BQ 0.15
- ENSC 0.10
- MACD
- BQ 0.03
- ENSC 0.03
- Stochastic Oscillator
- BQ 94.12
- ENSC 90.63
About BQ Boqii Holding Limited representing
Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.